Dutch firm ASML makes one of the most important pieces of machinery required to manufacture the most advanced chips in the world. U.S. chip curbs have left companies, including ASML, scrambling to figure out what the rules mean in practice.
Emmanuel Dunand | AFP | Getty Images
ASML, one of the most important semiconductor equipment companies in the world, beat top and bottom line expectations, but said it forecasts its revenue for this year will be similar to that of 2023.
Here’s how ASML did versus LSEG consensus estimates:
Net sales: 7.2 billion euros ($7.82 billion) versus 6.9 billion euros expected
Net profit: 2.05 billion euros versus 1.86 billion euros expected
ASML had previously said that it expects fourth-quarter net sales between 6.7 billion euros and 7.1 billion euros with a gross margin between 50% and 51%.
Net sales for the fourth quarter rose 12.5% year-on-year, while the company reported a gross margin of 51.4% in the fourth quarter.
ASML said it expects first-quarter net sales of between 5.0 billion euros and 5.5 billion euros.
“We maintain our conservative view for the total year and expect 2024 revenue to be similar to 2023. We also expect 2024 to be an important year to prepare for significant growth that we expect for 2025,” said ASML CEO Peter Wennink said in a statement on Wednesday.
ASML reported 27.6 billion euros in revenue for 2023, higher than the 21.2 billion euros of the year before. That was a 30% year-on-year rise.
China sales in focus
ASML, a Dutch company that makes a machine required in the manufacturing of the world’s most advanced chips, has been caught in the broader technology battle between the U.S. and China.
The Dutch government, following U.S. pressure, introduced curbs in June on the export of advanced semiconductor equipment. And in October, the U.S. tightened its own export controls on advanced semiconductors and chipmaking tools to China.
This month, ASML said the Dutch government partially revoked its license for the shipment of its NXT:2050i and NXT:2100i lithography systems in 2023 to China. These are systems required to make less advanced chips.
In a pre-recorded video released Wednesday, ASML Chief Financial Officer Roger Dassen said the company does not expect to get export licenses for the NXT:2000i and more advanced machines. Dassen also said it expects some China chip manufacturing plants not to get export licenses for the NXT:1970i and NXT:1980i immersion tools.
ASML previously said that export restrictions would impact 10% to 15% of China sales. There would be a similar impact in 2024, Dassen said.
ASML’s top end tools, known as extreme ultraviolet lithography machines, have never received an export license. To date, ASML has not shipped one of these machines to China.
Bitcoin briefly dropped below the $90,000 mark on Monday, extending its slide as investors continue to dump growth oriented assets like crypto and tech stocks.
The price of the flagship cryptocurrency was last lower by 3% at $91,358.66 to start the week, according to Coin Metrics. Earlier, it fell as low as $89,259.00. Bitcoin is down 10% in the past week.
Stock Chart IconStock chart icon
Bitcoin extends its slide as growth-oriented assets continue to get hit
“The need for liquidity is caused by FX spikes because of strong end-of-year U.S. economy number, the stock market rallying strong, and there are other places money is needed in the short-term,” said James Davies, co-founder and CEO at crypto trading platform Crypto Valley Exchange. “If we want bitcoin to act like a currency, we need to accept when it does, and this is one of those times. The U.S. Dollar has gotten stronger ad everything else including bitcoin is weaker when measured in dollars.”
Investor sentiment was optimistic coming into 2025, with markets looking forward to having a pro-crypto Congress and White House. That hope had outweighed any concern about macroeconomic-related speedbumps, until last week.
Investors are now warning that the first quarter of this year could be more turbulent for crypto than previously anticipated.
Bitcoin’s price grew 120% in 2024 but is down 3% so far in the new year.
Don’t miss these cryptocurrency insights from CNBC Pro:
Health-care payments company Waystar on Monday announced a new generative artificial intelligence tool that can help hospitals quickly tackle one of their most costly and tedious responsibilities: fighting insurance denials.
Hospitals and health systems spend nearly $20 billion a year trying to overturn denied claims, according to a March report from the group purchasing organization Premier.
“We think if we can develop software that makes people’s lives better in an otherwise stressful moment of time when they’re getting health-care, then we’re doing something good,” Waystar CEO Matt Hawkins told CNBC.
Waystar’s new solution, called AltitudeCreate, uses generative AI to automatically draft appeal letters. The company said the feature could help providers drive down costs and spare them the headache of digging through complex contracts and records to put the letters together manually.
Hawkins led Waystar through its initial public offering in June, where it raised around $1 billion. The company handled more than $1.2 trillion in gross claims volume in 2023, touching about 50% of patients in the U.S.
Claim denials have become a hot-button issue across the nation following the deadly shooting of UnitedHealthcare CEO Brian Thompson in December. Americans flooded social media with posts about their frustrations and resentment toward the insurance industry, often sharing stories about their own negative experiences.
Read more CNBC reporting on AI
When a patient receives medical care in the U.S., it kicks off a notoriously complex billing process. Providers like hospitals, health systems or ambulatory care facilities submit an invoice called a claim to an insurance company, and the insurer will approve or deny the claim based on whether or not it meets the company’s criteria for reimbursement.
If a claim is denied, patients are often responsible for covering the cost out-of-pocket. More than 450 million claims are denied each year, and denial rates are rising, Waystar said.
Providers can ask insurers to reevaluate claim denials by submitting an appeal letter, but drafting these letters is a time-consuming and expensive process that doesn’t guarantee a different outcome.
Hawkins said that while there’s been a lot of discussion around claims denials recently, AltitudeCreate has been in the works at Waystar for the last six to eight months. The company announced an AI-focused partnership with Google Cloud in May, and automating claims denials was one of the 12 use cases the companies planned to explore.
Waystar has also had a denial and appeal management software module available for several years, Hawkins added.
AltitudeCreate is one tool available within a broader suite of Waystar’s AI offerings called AltitudeAI, which the company also unveiled on Monday. AltitudeCreate rolled out to organizations that are already using Waystar’s denial and appeal management software modules earlier this month at no additional cost, the company said.
Waystar plans to make the feature more broadly available in the future.
“In the face of all of this administrative waste in health-care where provider organizations are understaffed and don’t have time to even follow up on a claim when it does get denied, we’re bringing software to bear that helps to automate that experience,” Hawkins said.
Through the collaboration, General Catalyst portfolio companies will use AWS’ services to build and roll out AI tools for health systems more quickly. Aidoc, which applies AI to medical imaging, and Commure, which automates provider workflows with AI, will be the first two companies to participate.
No financial terms were disclosed in the announcement.
“Without a strong partner like Amazon and AWS to stand alongside them, to co-develop and support these companies … it’s not going to move as fast as we hope,” Chris Bischoff, head of global health-care investing at General Catalyst, told CNBC in an interview.
Health systems are strained in the U.S., with staff burnout, growing labor shortages and razor-thin margins. These challenges often seem enticing for enterprising tech startups to tackle, especially as the multi-trillion dollar health-care industry dangles the prospect of large financial returns.
Hospitals operate in a complex, technology-weary and highly-regulated sector that can be difficult for startups to break into. General Catalyst is hoping to help its companies fast-track the development and go-to-market process by leveraging resources like computing power from AWS.
Read more CNBC reporting on AI
General Catalyst is no stranger to taking big swings in health-care.
The firm has closed more than 60 digital health deals since 2020, behind only Gaingels and Alumni Ventures, according to a December report from PitchBook. Last January, General Catalyst shocked the industry by announcing that its new business, the Health Assurance Transformation Company, planned to acquire an Ohio-based health system – an unprecedented move in venture capital.
General Catalyst’s “deep understanding” of health systems’ financial and operating realities made it an attractive partner for AWS, Dan Sheeran, AWS’ general manager of Healthcare & Life Science, told CNBC. Sheeran and Bischoff began outlining the collaboration between the two groups after meeting in London around nine months ago.
AWS also has an established presence in the health-care sector. The company offers more health- and life-sciences-specific services than any other cloud provider, according to a release, and it inked other high-profile AI partnerships with GE HealthCare, Philips and others last year.
The partnership between General Catalyst and AWS will stretch over several years, but new tools from Aidoc and Commure are coming in 2025. Aidoc is exploring how it can use the cloud to tap data modalities across pathology, cardiology, genomics and other molecular information, for instance.
Aidoc and Commure were selected to kick off the collaboration because they have both established a product-market fit, are operational and are focused on issues that are a high priority for AWS customers.
“GC has spent a lot of time thinking about how health systems can transform themselves, and we recognize that it’s not going to be through 1,000 companies, and we need solutions that are really enterprise grade,” Bischoff said. “Amazon shares the same vision, so we are starting with these two.”
Though the partnership between General Catalyst and AWS is still in its early days, the organizations said they believe it will help serve as a way to meet the market’s growing demand for new solutions.
“Health system leaders who want to realize the benefits of AI now have an easier way to accomplish that,” Sheeran said.